MONTVALE, N.J., July 12 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals
Corp. (Nasdaq: MEMY) today announced that it has completed enrollment in its
Phase 2a trial of MEM 3454, the company's lead nicotinic alpha-7 receptor
partial agonist, in Alzheimer's disease. The Company expects to report top-
line results for this trial in the fourth quarter of 2007.
"The rapidity with which we were able to complete enrollment of this
study, along with our recent announcement that we are planning to initiate a
proof-of-concept study in cognitive impairment associated with schizophrenia
(CIAS), underlines the enthusiasm we, our investigators and our partner Roche
have for MEM 3454," said Stephen R. Murray, M.D., Ph.D., Vice President of
Clinical Development. "We are pleased to have completed the trial's enrollment
in just a few months, remaining on track to share top-line data from two Phase
2a trials - MEM 3454 in Alzheimer's disease and MEM 1003 in Alzheimer's
disease - in the fourth quarter of this year."
The Phase 2a trial is a randomized, double-blind, placebo-controlled study
designed to assess the safety, tolerability and cognitive effects of three
doses of MEM 3454. The trial enrolled approximately 80 subjects with mild to
moderate Alzheimer's disease at multiple sites in the United States. Subjects
in the study were randomized at enrollment to receive 5 mg, 15 mg or 50 mg of
MEM 3454 or placebo once daily for a period of eight weeks. The primary
objective of the trial is to assess the effect of MEM 3454 using the Quality
of Episodic Secondary Memory (QESM) factor score from the Cognitive Drug
Research (CDR) battery. Secondary objectives include assessing the safety,
tolerability, and pharmacokinetics of multiple doses of MEM 3454 and the drug
candidate's effect on additional psychometric test items from the CDR battery
and the Alzheimer's Disease Assessment Scale -- Cognitive subscale.
MEM 3454 is a partial agonist of the nicotinic alpha-7 receptor, a highly
specialized receptor found in the central nervous system (CNS). Compounds
acting on this receptor could be beneficial in the treatment of Alzheimer's
disease and schizophrenia, as well as other psychiatric and neurological
disorders.
About the Company
Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on
developing innovative drugs for the treatment of debilitating CNS disorders
such as Alzheimer's disease, schizophrenia and depression. For additional
information, please visit our website at http://www.memorypharma.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that are subject to
risks and uncertainties. All statements, other than statements of historical
facts, regarding management's expectations, beliefs, goals, plans or Memory
Pharmaceuticals' prospects, future financial position, future revenues and
projected costs should be considered forward-looking. Readers are cautioned
that actual results may differ materially from projections or estimates due to
a variety of important factors, including the risks and uncertainties
associated with: obtaining additional financing to support Memory
Pharmaceuticals' R&D and clinical activities and operations; the outcome of
clinical trials of Memory Pharmaceuticals' drug candidates and whether they
demonstrate these candidates' safety and effectiveness; obtaining regulatory
approvals to conduct clinical trials and to commercialize Memory
Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter
into and maintain collaborations with third parties for its drug development
programs; Memory Pharmaceuticals' dependence on its collaborations and its
license relationship with Bayer; achieving milestones under Memory
Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on
preclinical and clinical investigators, preclinical and clinical research
organizations, manufacturers and consultants; and protecting the intellectual
property developed by or licensed to Memory Pharmaceuticals. These and other
risks are described in greater detail in Memory Pharmaceuticals' filings with
the Securities and Exchange Commission. Memory Pharmaceuticals may not
actually achieve the goals or plans described in its forward-looking
statements, and investors should not place undue reliance on these statements.
Memory Pharmaceuticals disclaims any intent or obligation to update any
forward-looking statements as a result of developments occurring after the
date of this press release.
SOURCE Memory Pharmaceuticals Corp.
-0- 07/12/2007
/CONTACT: Jzaneen Lalani, General Counsel, +1-201-802-7249; or Laura
Perry of Stern Investor Relations, Inc., +1-212-362-1200, both for Memory
Pharmaceuticals Corp./
/Web site: http://www.memorypharma.com /
(MEMY)
CO: Memory Pharmaceuticals Corp.
ST: New Jersey
IN: BIO HEA MTC
SU: TRI
DO-KM
-- NYTH112 --
9944 07/12/2007 16:10 EDT http://www.prnewswire.com
